Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met

LIPELLA PHARMACEUTICALS INC.

All 27 patients completed 4-week treatment; no serious adverse events reported.
76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.
Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.
Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001753926-25-001525
form_type: 8-K
ticker: LIPO
cik: 0001347242
company_name: LIPELLA PHARMACEUTICALS INC.
filed_at: 2025-09-18T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.791747+00:00
generated_at: 2026-05-17T06:13:27.616989+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001753926-25-001525
json_url: https://secwatch.observer/filing/0001753926-25-001525.json
markdown_url: https://secwatch.observer/filing/0001753926-25-001525.md
text_url: https://secwatch.observer/filing/0001753926-25-001525.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/0001753926-25-001525-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/g084955_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001753926-25-001525

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.